Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gossele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Dohner H, Chiosis G, Glimm H, Frohling S, Scholl C
J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.